|
Patent landscape, scope, and claims: |
United States Patent 10,201,584: Scope, Claims, and Landscape Analysis
United States Patent 10,201,584, titled "Pharmaceutical Compositions Comprising 5-Oxo-1,4-diazepane Derivatives," was granted to Merck Sharp & Dohme Corp. on February 12, 2019. The patent covers pharmaceutical compositions containing specific 5-oxo-1,4-diazepane derivatives, primarily targeting the treatment of inflammatory conditions. The primary active pharmaceutical ingredient (API) described within the patent is MK-8722, a potent Janus kinase (JAK) inhibitor.
What is the Primary Therapeutic Target of Patent 10,201,584?
The patent primarily targets the treatment of inflammatory and autoimmune diseases. The claimed pharmaceutical compositions are designed to inhibit Janus kinase (JAK) signaling pathways, which are implicated in the pathogenesis of numerous inflammatory disorders.
- Inflammatory Diseases: These include conditions characterized by chronic inflammation, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel disease.
- Autoimmune Diseases: Conditions where the immune system mistakenly attacks the body's own tissues.
- JAK Inhibition: The core mechanism involves modulating the JAK-STAT signaling pathway. This pathway plays a crucial role in cytokine signaling, immune cell differentiation, and inflammatory responses. By inhibiting JAK enzymes, the compositions aim to reduce the production and activity of inflammatory mediators.
What Specific Compounds Are Covered by the Patent?
Patent 10,201,584 claims pharmaceutical compositions containing specific 5-oxo-1,4-diazepane derivatives. The most prominent compound disclosed and exemplified within the patent is MK-8722.
- MK-8722: This compound is a selective inhibitor of JAK1 and JAK2. Its chemical structure and properties are detailed within the patent.
- Chemical Name: (2S)-2-({3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}carbonyl)-5-oxopyrrolidine-1-carboxamide.
- Mechanism of Action: Inhibits JAK1 and JAK2, thereby blocking downstream signaling of various pro-inflammatory cytokines.
- Generality of Claims: The patent also covers a broader genus of 5-oxo-1,4-diazepane derivatives, providing protection for related compounds with similar structural features and therapeutic utility. These claims are often defined by Markush structures, encompassing a range of substituents and modifications around a core scaffold.
What Are the Key Claims of United States Patent 10,201,584?
The claims of Patent 10,201,584 define the legal boundaries of the patent protection. They are broadly categorized into compound claims, composition claims, and method of treatment claims.
- Claim 1 (Composition): "A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of Formula (I): [chemical structure of Formula (I) is provided]"
- Formula (I): This encompasses the specific 5-oxo-1,4-diazepane derivatives, including MK-8722, as well as related structures defined by substituents and stereochemistry.
- Pharmaceutically Acceptable Carrier: Standard excipients and diluents used in drug formulation.
- Effective Amount: A quantity sufficient to elicit a therapeutic response.
- Claim 2 (Specific Compound within Formula I): "The pharmaceutical composition of claim 1, wherein the compound is MK-8722."
- This claim narrows the scope to the specific compound MK-8722, providing more precise protection for this particular API.
- Claim 3-10 (Further Compositional Limitations): These claims further define the composition by specifying dosage forms, excipients, or particular salt forms of the active compound.
- Dosage Forms: Oral dosage forms such as tablets, capsules, or powders are often specified.
- Excipients: Inclusion of specific fillers, binders, disintegrants, or lubricants.
- Claim 11-15 (Method of Treatment): These claims cover the use of the pharmaceutical compositions for treating specific diseases.
- Methods of Treating Inflammatory Diseases: Claims detail the use for treating conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel disease.
- Dosage Regimen: The claims may also implicitly or explicitly refer to a dosage regimen for administering the composition to a patient in need thereof.
- Claim 16-20 (Polymorphs and Salts): Claims can extend to specific crystalline forms (polymorphs) or pharmaceutically acceptable salts of the active compounds, providing broader protection.
What is the Patent Landscape for JAK Inhibitors?
The patent landscape for JAK inhibitors is highly competitive and crowded, with numerous pharmaceutical companies holding patents covering various aspects of these therapies, including novel compounds, formulations, and methods of use. Patent 10,201,584 is situated within this dynamic environment.
- Key Players: Major pharmaceutical companies with significant patent portfolios in JAK inhibitors include:
- AbbVie: Known for its JAK inhibitor upadacitinib (Rinvoq).
- Pfizer: Holder of tofacitinib (Xeljanz), one of the earliest approved JAK inhibitors.
- Eli Lilly and Company: Developer of baricitinib (Olumiant).
- Incyte Corporation: Significant player with ruxolitinib (Jakafi).
- Bristol Myers Squibb: Holds patents related to deucravacitinib (Sotyktu).
- Patent Strategies: Companies employ diverse patenting strategies to protect their JAK inhibitor assets. This includes:
- Composition of Matter Patents: Covering novel chemical entities (like MK-8722).
- Formulation Patents: Protecting specific drug delivery systems, dosage forms, and excipient combinations.
- Method of Use Patents: Claiming the treatment of specific indications with a particular JAK inhibitor.
- Process Patents: Covering novel synthetic routes for manufacturing the API.
- Polymorph Patents: Protecting specific crystalline forms that may offer improved stability or bioavailability.
- Patent Expirations: As patents expire, opportunities for generic competition emerge, impacting market dynamics and pricing. Companies often seek to extend market exclusivity through secondary patents, such as formulation or method of use patents, that may have later expiration dates.
- Litigation and IPRs: The competitive landscape frequently leads to patent litigation, including challenges to patent validity through Inter Partes Reviews (IPRs) at the U.S. Patent and Trademark Office (USPTO).
What Are the Potential Market Implications of Patent 10,201,584?
The implications of Patent 10,201,584 are tied to the development and commercialization of the drug candidates it protects, primarily MK-8722.
- Exclusivity for Merck: The patent provides Merck Sharp & Dohme Corp. with market exclusivity for the claimed compositions and methods of treatment. This exclusivity period is crucial for recouping R&D investments.
- Pipeline Development: MK-8722, as described in this patent, has been a subject of clinical development by Merck for various inflammatory conditions. The patent's validity and remaining term are critical for Merck's ongoing R&D and commercialization strategies for this compound.
- Competitive Positioning: The strength and breadth of the claims within Patent 10,201,584 influence Merck's competitive position against other companies developing JAK inhibitors. If the claims are broad and robust, they can deter competitors from developing similar compounds or formulations.
- Generic Entry: Upon patent expiration, generic manufacturers may seek to enter the market. The existence of other patents (e.g., formulation patents) held by the innovator can delay or complicate generic entry.
- Licensing Opportunities: In some scenarios, patent holders may license their technology to other companies, creating revenue streams and expanding the reach of the patented technology.
What is the Status of MK-8722 in Clinical Development?
MK-8722 is a dual JAK1/JAK2 inhibitor that has been investigated by Merck for various inflammatory and autoimmune diseases.
- Clinical Trials: Merck has conducted clinical trials for MK-8722 across several indications.
- Rheumatoid Arthritis: Studied in Phase II and Phase III clinical trials.
- Psoriatic Arthritis: Evaluated in clinical studies.
- Inflammatory Bowel Disease: Investigated for conditions like ulcerative colitis and Crohn's disease.
- Development Program: The patent directly supports the development of MK-8722 by protecting its composition and therapeutic use.
- Regulatory Submissions: Successful clinical trial results would be a prerequisite for regulatory submissions to bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The patent plays a role in securing market exclusivity upon potential approval.
- Comparison to Other JAK Inhibitors: MK-8722 competes in a market with established JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. Its clinical profile, including efficacy, safety, and selectivity, determines its potential to capture market share.
What Are the Key Takeaways?
- United States Patent 10,201,584 protects pharmaceutical compositions containing specific 5-oxo-1,4-diazepane derivatives, notably MK-8722, a JAK1/JAK2 inhibitor.
- The patent claims cover the chemical compounds, pharmaceutical compositions, and methods for treating inflammatory and autoimmune diseases.
- The JAK inhibitor patent landscape is highly competitive, with major pharmaceutical companies holding extensive portfolios.
- Patent 10,201,584 provides Merck Sharp & Dohme Corp. with market exclusivity for MK-8722, influencing its competitive standing and R&D strategy.
- MK-8722 has been evaluated in clinical trials for indications including rheumatoid arthritis and inflammatory bowel disease.
Frequently Asked Questions
-
What is the expiration date of Patent 10,201,584?
The expiration date is typically 20 years from the filing date, subject to adjustments for patent term extensions. For Patent 10,201,584, filed on July 19, 2016, the base expiration would be July 19, 2036, potentially extended by the U.S. Patent and Trademark Office.
-
Does Patent 10,201,584 cover methods of manufacturing MK-8722?
This patent primarily focuses on the composition of matter and pharmaceutical compositions, and methods of treatment. It is unlikely to cover detailed manufacturing processes, which would typically be protected by separate process patents.
-
Can other companies develop drugs with similar structures to MK-8722?
Other companies may develop drugs with similar structures if those structures are not covered by the claims of Patent 10,201,584 or other relevant patents. Patent claims are narrowly interpreted, and slight structural modifications could fall outside the scope of protection.
-
What are the primary indications for which MK-8722 has been tested?
MK-8722 has been tested for rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease, among other inflammatory and autoimmune conditions.
-
How does MK-8722 differ from other approved JAK inhibitors in terms of selectivity?
MK-8722 is a dual JAK1/JAK2 inhibitor. Other JAK inhibitors have varying selectivity profiles, with some being pan-JAK inhibitors (inhibiting JAK1, JAK2, JAK3, and TYK2), while others are more selective for specific JAK isoforms (e.g., JAK1-selective or JAK2-selective). This selectivity can influence their therapeutic efficacy and side-effect profiles.
Citations
[1] Merck Sharp & Dohme Corp. (2019). Pharmaceutical Compositions Comprising 5-Oxo-1,4-diazepane Derivatives (U.S. Patent No. 10,201,584). Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/
[3] ClinicalTrials.gov. (n.d.). Search Results for MK-8722. Retrieved from https://clinicaltrials.gov/
More… ↓
⤷ Start Trial
|
